When do biologic drug patents expire and when will biosimilars launch?

US 10,137,196: What do the claims cover, where they break, and how crowded the sacituzumab govitecan landscape is?

United States Patent 10,137,196 is a method-of-treatment patent built around one core payload: sacituzumab govitecan (IMMU-132/Trodelvy). The claims are directed to treating a wide panel of solid tumors in humans by administering that immunoconjugate at defined dose ranges to patients who have failed other therapies or are resistant/relapsed, with additional dependent claim scaffolding around tumor size reduction thresholds, specific cancer subtypes, and combination therapy lists.

The landscape risk is not the breadth of indications by itself. The risk is that the claims read like a permutation layer over an already-commercial immunoconjugate and already-established clinical use patterns, with many “generic” recitations that are difficult to distinguish from prior art combination/relapsed-treatment frameworks, dose ranges, and response-based endpoints.

What is the claim core and how broad is it in practice?

Claim set is a relapsed/refractory method using one fixed drug

All independent concept coverage in the excerpt is anchored to:

Immunoconjugate: sacituzumab govitecan
Patients: humans with cancers selected from a long list
On-label condition in substance: patient has failed to respond to at least one other therapy, or is resistant to or relapsed from therapy with a camptothecin
Dose: 6–16 mg/kg (with dependent dose bands)
Additional optional constraints: metastatic setting, response thresholds, specific tumor subtype groups, irinotecan failure, and combination therapy with broadly enumerated anticancer modalities

Independent claims presented:

Claim 1 (baseline “failed at least one other therapy” + dose 6–16 mg/kg)
Claim 17 (camptothecin-resistant/relapsed specifically + dose 6–16 mg/kg)

Everything else shown is dependent.

Indication breadth is wide (10+ solid tumor categories)

From the provided claims, cancer categories include:

colorectal
lung
stomach
urinary bladder
renal
pancreatic
breast
ovarian
uterine
esophageal
urothelial
prostatic

This is not a mechanistic targeting claim. It is a clinical use claim designed to cover multiple approved or investigational settings where sacituzumab govitecan is deployed.

Dose is broad enough to overlap common clinical regimens

Main range: 6–16 mg/kg
Dependent, narrower options: 8–12 mg/kg and 8–10 mg/kg
Another dependent enumerates specific dosages including 6, 7, 8, 9, 10, 11, 12, 16 mg/kg (Claim 2)

This structure is a classic “dose coverage net”: it is wide enough to catch standard starting/adjustment doses and broad enough to create literal coverage without needing a narrow, uniquely claimed regimen.

How critical are the dependent claims for enforceability?

Dependent claims can help narrow to patentable subspaces, but here they mostly add qualifiers that frequently map to already-understood trial endpoints or routinely used clinical categorization.

Dose subranges (Claims 2, 9, 10)

6–16 mg/kg (Claim 1 / 17)
Specific values include 6, 7, 8, 9, 10, 11, 12, 16 mg/kg (Claim 2)
8–12 mg/kg (Claim 9)
8–10 mg/kg (Claim 10)
8–12 mg/kg repeated in Claim 19; 8–10 mg/kg repeated in Claim 20

Critical point: If prior art teaches sacituzumab govitecan in relapsed cancer patients with dosing in these ranges, the dependent claims may not restore novelty. They can still matter if earlier art used different dosing bands or different patient selection criteria.

Response-based endpoints (Claim 3)

Claim 3 adds tumor size reduction thresholds:

at least 15%, 20%, 30%, or 40%

Critical point: Response metrics like objective response rate and tumor shrinkage are standard oncology endpoints. If earlier clinical studies on sacituzumab govitecan already reported these levels and associated them with use in relapsed settings, then the claim risks being treated as an expected/obvious result rather than a distinguishing feature. If earlier art does not tie those thresholds to dosing and patient selection, Claim 3 could still create separation, but the excerpt does not show any unique method step beyond administering the drug.

Subtype selection (Claim 4)

Claim 4 restricts cancer to:

triple-negative breast cancer
HER+ breast cancer
ER+ breast cancer
progesterone+ breast cancer
metastatic non-small-cell lung cancer
metastatic small-cell lung cancer
metastatic urothelial cancer
metastatic pancreatic cancer

Critical point: This is an oncology taxonomy layer. It can be valuable if earlier art taught sacituzumab govitecan only in other tumor groups. If earlier art already includes these metastatic subtypes, novelty advantage drops sharply.

Irinotecan failure / camptothecin resistance (Claims 5, 17-18)

Claim 5: failed/relapsed from irinotecan prior to sacituzumab govitecan
Claim 17: resistant to or relapsed from therapy with camptothecin
Claim 18: camptothecin includes irinotecan, topotecan, SN-38

Critical point: The camptothecin limitation is the most operationally meaningful narrowing in the excerpt. Many oncology regimens for advanced colorectal and certain lung/urothelial contexts include camptothecin derivatives directly or indirectly. If prior art already treated camptothecin-refractory patients with sacituzumab govitecan, then the claim narrows to a population that is already taught.

If prior art treated those patients but used different dosing, different clinical framing, or different drug combination, then the claim could still carve out.

Combination therapy scaffolding (Claims 11–16)

Claim 11 adds:

further administering at least one other anti-cancer therapy selected from a long list, including
- surgery
- external radiation
- radioimmunotherapy
- immunotherapy
- chemotherapy
- antisense therapy
- interference RNA therapy
- “treatment with a therapeutic agent”
- gene therapy

Claims 12–16 then define what “therapeutic agent” could be using extremely broad and comprehensive open-ended lists:

Claim 12: drug/toxin/immunomodulator/second antibody/etc.
Claim 13: huge enumeration including many standard oncology agents, with irinotecan (CPT-11) and SN-38 explicitly included
Claim 14: immunomodulator list with broad cytokine and factor coverage
Claim 15: radionuclide list with extensive isotopes
Claim 16: toxin list

Critical point: This is extremely broad. It creates coverage for any combination partner that fits the category. It also raises validity risk: the combination step is generic, and the dependent claims provide no required mechanism, sequence, schedule, or specific pairing to sacituzumab govitecan. In many jurisdictions, this is where obviousness attacks often concentrate.

What does the patent attempt to protect strategically?

A “labeling” claim around an existing product

US 10,137,196 reads less like a new conjugate chemistry patent and more like a clinical-use/administration patent trying to lock in:

Drug identity: sacituzumab govitecan
Cancer panel: multiple solid tumor categories
Treatment line context: relapsed/refractory after other therapy, plus camptothecin resistance for at least one claim family
Dose bands: 6–16 mg/kg and subsets
Optional clinical endpoints: tumor shrinkage thresholds

This pattern is typical of follow-on patents meant to extend exclusivity around known assets by adding use conditions.

Enforceability pressure points

The strongest enforceability angle is where the claims require a specific patient selection criterion that earlier art did not teach with sacituzumab govitecan, notably:

camptothecin (irinotecan/topotecan/SN-38) resistant or relapsed prior to sacituzumab govitecan (Claims 17–18)
irinotecan failure specifically (Claim 5)

The weakest enforceability angles are:

very broad indication lists (Claims 1 and 17)
broad dose range (6–16 mg/kg)
generic combination therapy scaffolds (Claims 11–16)
outcome thresholds (Claim 3) that may be treated as expected results unless tied to an unusual method step

Patent landscape: how crowded is sacituzumab govitecan “use” coverage likely to be?

Commercial and regulatory reality drives prior art saturation

Sacituzumab govitecan is a well-established immunoconjugate in oncology. In a crowded landscape, follow-on patents that claim:

“administer sacituzumab govitecan to relapsed patients”
“at a standard dose range”
“in standard solid tumor indications” tend to face steep validity headwinds because the clinical literature and earlier filings often already disclose these concepts.

Claim design suggests an attempt to sit between prior disclosures

This patent tries to thread three needles:

Dose granularity: enumerated dose values and narrow sub-ranges
Treatment-line filter: “failed one other therapy” and camptothecin resistance/relapse
Endpoint inclusion: tumor shrinkage thresholds

Each of those elements can be distinguishing if earlier art is incomplete on at least one axis. But if earlier art includes all three axes, the novelty collapses.

Most obvious prior-art targets (by claim wording)

Even without reviewing specific citations here, the excerpt itself shows likely prior art categories:

sacituzumab govitecan phase 1/2/3 trials in relapsed/refractory solid tumors
publications describing dosing and dose modifications in ranges overlapping 6–16 mg/kg
subgroup analyses in triple-negative and other breast cancer populations
studies enrolling irinotecan/camptothecin-refractory patients in colorectal or other settings
standard trial response metrics reporting percent tumor shrinkage or ORR-related distributions

Because the claims do not require a unique administration schedule, unique premedication, or unique combination partner, the patent’s differentiation must come from the exact combination of:

patient selection + dose band + administration

That is where litigation often becomes a document-heavy factual dispute: what prior trials actually enrolled and how their dosing bands map onto the claimed ranges.

Critical claim-by-claim risk map (based on internal structure)

Claim	Key limitation(s) from excerpt	Primary separation potential	Primary validity risk
1	sacituzumab govitecan; cancer panel; dose 6–16 mg/kg; patient failed at least one therapy	broad patient-line filter if earlier art used different populations or different dose band	if earlier art already covers relapsed solid tumors at these dose ranges, risk is high
2	specific doses (6,7,8,9,10,11,12,16 mg/kg)	helps if prior art used different discrete dosing	if prior art includes any of these exact doses, risk increases
3	tumor size reduction threshold(s) 15/20/30/40%	creates “result” constraint if not taught previously	expected response metrics are often easy to map to prior art endpoints
4	specific metastatic breast/lung/urothelial/pancreatic subtype list	useful if earlier art excluded these subtypes	if these subtypes are already included, risk rises
5	irinotecan failure before treatment	most operationally meaningful if earlier art used other refractory contexts	if prior trials enrolled irinotecan-refractory populations, risk rises
6	“cancer refractory to other therapies but responds”	weak if “responds” is inherent to clinical setting	likely obvious/subjective unless anchored to a method step
7	metastatic disease	weak if metastatic setting is standard	metastatic enrollment is common in later-line trials
8	reduce or eliminate metastases	weak result language	obvious to clinicians; may be non-distinguishing
9	dose 8–12 mg/kg	narrows dose band	if prior art overlaps, risk remains
10	dose 8–10 mg/kg	further narrows	likely overlaps standard dosing
11	generic combination therapy option	could capture real-world combos	combination step is generic; easy to attack
12–16	extremely broad lists of agent classes/toxins/radionuclides	very broad coverage	breadth can hurt validity; reads like “any” combination
17	sacituzumab govitecan; camptothecin resistant/relapsed; dose 6–16 mg/kg	best narrowing lever in excerpt	if prior art includes camptothecin-refractory patients, risk rises
18	camptothecin includes irinotecan/topotecan/SN-38	clarifies scope	if trials clearly used these agents, risk rises
19–20	dose subranges 8–12 and 8–10 for Claim 17	dose narrowing	overlap likely

What would a freedom-to-operate or investment diligence screen look for (claim-mapped)?

A diligence screen should focus on whether the prior art teaches the same combination of:

sacituzumab govitecan administration
relapsed/refractory patient selection
dose within 6–16 mg/kg and specifically 8–10 or 8–12
for Claim 17 family: camptothecin resistance/relapse (irinotecan/topotecan/SN-38)

The claims are structured so that if even one axis matches earlier disclosure, the enforceability narrative weakens. The most leverage sits with the camptothecin limitation because it is more specific than the generic “failed at least one therapy” language.

Key Takeaways

US 10,137,196 is a use-and-dosing patent built around sacituzumab govitecan for relapsed/refractory solid tumors with broad indication coverage and dose ranges spanning 6–16 mg/kg.
The strongest distinguishing limitation in the excerpt is camptothecin resistance/relapse (Claims 17–18) and irinotecan failure (Claim 5). These create a narrower patient-population filter than the general “failed at least one therapy” language.
Many dependent claims add standard oncology elements (metastatic status, tumor shrinkage thresholds, generic combination therapy lists). These are often easier to map to prior art and can be vulnerable on obviousness if earlier trials already taught similar dosing and patient selection.
From a landscape standpoint, the breadth of indications plus the broad dose net suggests high prior art saturation risk, especially if earlier sacituzumab govitecan clinical and patent literature already includes relapsed populations and the same dosing bands.

FAQs

1) What is the main subject matter of US 10,137,196?

It is a method of treating humans with solid tumors by administering sacituzumab govitecan at defined dose ranges to patients who have failed prior therapy, including a subset where the patient is camptothecin-resistant or camptothecin-relapsed.

2) Which claim language most narrows the covered patient population?

Claims 17–18 narrow to patients resistant/relapsed to camptothecin (including irinotecan, topotecan, SN-38) prior to sacituzumab govitecan.

3) Do the claims require a specific tumor biomarker?

No biomarker requirement appears in the independent claim text provided. Claim 4 adds subtype selection for breast cancer phenotypes and metastatic subtypes for lung/urothelial/pancreatic, but not via a required biomarker-testing step.

4) How tight are the dose claims?

The headline range is broad (6–16 mg/kg). Dependent claims narrow to 8–12 mg/kg and 8–10 mg/kg, and Claim 2 lists discrete dose values including 6, 7, 8, 9, 10, 11, 12, 16 mg/kg.

5) Where is validity risk likely highest inside the claim set?

Where claims rely on generic combination therapy categories (Claims 11–16) and outcome/result language like tumor shrinkage thresholds (Claim 3) without additional unique method steps.

References

[1] United States Patent 10,137,196 (claims excerpt provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978	10,137,196	2036-03-14
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	January 23, 2015	10,137,196	2036-03-14
Gilead Sciences, Inc.	TRODELVY	sacituzumab govitecan-hziy	For Injection	761115	April 22, 2020	10,137,196	2036-03-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,137,196

Summary for Patent: 10,137,196